These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 36900330)
1. Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma. Al Khatib MO; Pinton G; Moro L; Porta C Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900330 [TBL] [Abstract][Full Text] [Related]
2. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336 [TBL] [Abstract][Full Text] [Related]
4. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475 [TBL] [Abstract][Full Text] [Related]
5. [Anti-tumor immunotherapy in malignant pleural mesothelioma]. Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822 [TBL] [Abstract][Full Text] [Related]
6. New therapeutic strategies for malignant pleural mesothelioma. Bonelli MA; Fumarola C; La Monica S; Alfieri R Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778 [TBL] [Abstract][Full Text] [Related]
7. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Nicolini F; Bocchini M; Bronte G; Delmonte A; Guidoboni M; Crinò L; Mazza M Front Oncol; 2019; 9():1519. PubMed ID: 32039010 [TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332 [TBL] [Abstract][Full Text] [Related]
9. Updates in the diagnosis and treatment of malignant pleural mesothelioma. Katzman D; Sterman DH Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973 [TBL] [Abstract][Full Text] [Related]
10. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Zhang W; Wu X; Wu L; Zhang W; Zhao X Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399 [TBL] [Abstract][Full Text] [Related]
15. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study. Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T Oncology; 2021; 99(3):161-168. PubMed ID: 33053560 [TBL] [Abstract][Full Text] [Related]
16. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review). Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640 [TBL] [Abstract][Full Text] [Related]
17. Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma. Cheng L; Li N; Xu XL; Mao WM Curr Drug Targets; 2020; 21(15):1606-1612. PubMed ID: 32682370 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment. Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T Front Oncol; 2020; 10():554570. PubMed ID: 33381446 [TBL] [Abstract][Full Text] [Related]
19. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. Harber J; Kamata T; Pritchard C; Fennell D J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518291 [TBL] [Abstract][Full Text] [Related]